Lausanne, 8th November 2018 – TESA, leader in precision measurement tools, BOBST, worldwide supplier of machines for packaging manufacturers, and SOPHiA GENETICS, world leader in data-driven medicine, were rewarded for their achievements at the PVEI this Thursday evening at the IMD Business School in front of 300 guests. Collectively awarded by the Department of Economics, Innovation and Sport (DEIS), the Vaud Chamber of Commerce and Industry (CVCI) and Economic Development – Vaud (DEV), this award recognises three companies that are both excelling beyond our borders and also the driving powers of Vaud’s economy.

Founded in 1941 and based in Renens, TESA SA blew away the competition in its category “Foreign Business”. The company, which makes precision measurement tools, hand-held tools and measuring sensors, became part of the Swedish group Hexagon, a global supplier of information technology, in 2001. Many of its innovations were made possible thanks to collaborations with universities in the region, in particular the EPFL. Currently, TESA has around 800 employees around the world, with 300 based in Renens (13 of whom are apprentices). Their main clients are in the mechanic, automotive and medical industries, giving them an annual revenue of almost CHF 100,000,000. As well as the site in Renens, the company has affiliates in Europe, Japan and the USA, and a factory in China.

Outstanding in its category “Swiss Business”, BOBST, world leader in packaging and labelling solutions, has been around for 128 years. The company has more than 5,400 employees around the world, with some 2,000 in Vaud (of whom around 200 are apprentices). To stay at the height of innovation, the company is built around 4 principles: to learn, innovate, industrialise and establish. Last year in Cheseaux, the company also created the start-up Mouvent, its Centre of Expertise in digital printing. Currently, 25,500 BOBST machines are used worldwide. The company has sales and service networks in more than 50 countries and production sites across three continents. In 2017, BOBST’s revenue rose to CHF 1,528,000,000.

SOPHiA GENETICS, founded in 2011 at the EPFL, set itself apart in the category “Jury’s special prize”. Based in Saint-Sulpice since 2014, the company currently has 66 employees in the region and some 130 around the world. This world leader in Data-Driven Medicine created the AI SOPHiA and works with a network of more than 850 hospitals in 77 countries. SOPHiA technology is used by hundreds of university hospitals around the world in order to better diagnose and treat patients thanks to an ultra-precise analysis of genomic data. As well as clinical genomics, the analytical power of SOPHiA also now corresponds to the needs of radiology and clinical trials. Responding to growing demand in the American market, an operational centre was opened in Boston last September. Currently, 20 employees work in the USA, a number that should grow to 50 in the next year.

The award ceremony returned on 8th November with its panel of judges and three organisers. Presided over by Philippe Leuba, Head of DEIS, this year’s panel consisted of Aude Pugin, President of CVCI, Manuel Leuthold, President of DEV, Jean-Philippe Bonardi, Professor and Dean of HEC Lausanne and Dominique Turpin, Dean of External Relations at IMD in Lausanne. The previous year’s winners were also present – Thibaud Stoll, Head of Global Biotech Manufacturing at Merck Group, Alexandre Pesci, CEO of LEMO and André Wider, CEO of Wider SA.

One award, three categories

Since 2014, every autumn the PVEI honours three businesses both active internationally and represented in the canton of Vaud. The prize winners are chosen based on a series of criteria, including the presence of a head office in the region for at least 3 years, a contribution to the canton’s image beyond the national boundaries and the creation of jobs locally. The category “Foreign company” takes into account local production of goods or services, economic diversification, local subcontracting and integration. The winner of the “Swiss company” category is chosen according to criteria such as professional development, scientific collaborations and international expansion. The “Jury’s special prize” honours a particularly innovative business, committed to the region and collaborating with other local businesses.

SAN ANTONIO, TX and HAYWARD, CA - October 31, 2018– Paragon Genomics, Inc., a leader in amplicon-based target enrichment and library preparation solutions for next-generation sequencing (NGS) assays today announced a partnership with SOPHiA GENETICS designed to accelerate the global adoption of Data-Driven Medicine worldwide. Under the terms of the agreement, Paragon Genomics’ CleanPlex^® NGStarget enrichment technologies will be incorporated in the SOPHiA AI Platform. The partnership is being announced at the Association for Molecular Pathology 2018 Annual Meeting (AMP 2018).

Paragon Genomics' CleanPlex is a proprietary, ultra-high multiplexed NGS target enrichment technology that allows a large number of targets to be interrogated rapidly and accurately using a streamlined workflow with superior analytical performance. The CleanPlex technology is provided as ready-to-use and custom NGS panels and is available for use with Illumina or Ion Torrent platforms. CleanPlex will now also be incorporated in the SOPHiA AI Platform, providing a comprehensive and standardized solution for accurate genomic detection and characterization of all types of tumor alterations in a single test.

Tao Chen, co-founder and CEO of Paragon Genomics, said, "This partnership with SOPHiA GENETICS greatly expands the universe of cancer experts able to benefit from our proprietary CleanPlex target enrichment technologies. The best-in-class SOPHiA AI technology currently reaches a large and growing global community of hospitals and laboratories, which use its universal platform to achieve exceptional analytical performance. The worldwide launch of this partnership will provide immediate access to our combined solutions, enabling these providers to more rapidly and precisely identify tumor mutations and improve the throughput, quality and reliability of their sequencing results."

Jurgi Camblong, CEO and co-founder of SOPHiA GENETICS, commented, "This new partnership reflects our ongoing commitment to provide our global community of healthcare institutions with the most effective genomic solutions available, thereby accelerating the adoption of Data-Driven Medicine. Paragon technology has proven to be a very solid Amplicon-based technology that will definitively benefit to users of our SOPHiA AI Platform for Oncology applications." 

San Diego, USA – October 17^th, 2018 – SOPHiA GENETICS, leader in Data-Driven Medicine, has announced today from the annual meeting of the American Society of Human Genetics (ASHG), the release of Alamut Genova, the advanced variant exploration software for genomic data visualization and interpretation.

Alamut Genova is the latest evolution of Alamut Visual, already trusted by over 500 healthcare institutions worldwide. The powerful new decision-support technology, Alamut Genova is now a full genome browser, further enabling clinical researchers to easily assess the pathogenic status of human alterations. The software graphically displays complex genomic information, integrated from various curated sources and prediction algorithms in one user-friendly environment.

This new version has been redesigned to empower geneticists to solve complex genomic interpretation cases more intuitively. Alamut Genova offers a series of novel and efficient features, including ACMG/AMP classification, 3D protein visualization, Sanger electropherogram visualization and new splicing predictions that complete the existing solution.

Combining the analytical power of SOPHiA AI platform with the advanced visualization software Alamut Genova, geneticists can now benefit from a comprehensive solution to precisely identify and fully explore variants associated with hereditary disorders and cancer. SOPHiA accurately detects and annotates all types of alterations and redirects complex variants to Alamut Genova in order to assess them in the exact genomic context. This is particularly impactful for large gene panels, full exomes and genomes, where a large number of newly detected genomic variants and variants of unknown significance (VUS) are identified.

André Blavier, Scientific Director at SOPHiA GENETICS, said: “The combined use of SOPHiA and Alamut Genova provides clinical researchers with a unique and complete solution, supporting them all the way from precise genomic variant detection to proper interpretation. This new release marks a step forward in increasing experts’ adoption of Data-Driven Medicine.”

Lausanne, September 27, 2018 - SOPHiA GENETICS has received yesterday evening at the Convergence in Oncology Summit (Biopôle – Lausanne), the “Salus Partner Excellence in HealthTech Award”. This prize recognizes the company’s progress in the democratization of Data-Driven Medicine. 


SOPHiA GENETICS is a health tech company that has developed SOPHiA AI, the most advanced and used technology for Data-Driven Medicine. SOPHiA helps clinicians better diagnose, treat and monitor patients thanks to accurate and standardized clinical genomics analysis. SOPHiA supports the diagnosis of 1 patient every 5 minutes, +250’000 to date.  

Upon receiving the award Dr Jurgi Camblong CEO and co-founder of SOPHiA GENETICS comments: “In the context of Convergence in Oncology, our mission is to allow and encourage knowledge sharing, key to deliver disruptive solutions in the fight against cancer. We are very happy and honored to receive the 2018 Salus Excellence in HealthTech Award. It is again the recognition of our teamwork dedicated to help as many patients as possible worldwide.”

“SOPHiA GENETICS joins a prestigious group of companies recognized by the Salus Partners Excellence in Health Tech Award. They are a great example of the flourishing innovation in Health Tech in Switzerland.” says Dr. Brian Hashemi, Co-Organizer of the Convergence in Oncology Summit and Managing Partner of the investment firm Salus Partners.

Previous winners of the award have been experiencing great momentum: Endosense - a Geneva-based company in cardiac ablation, acquired by St. Jude for CHF300mm. Sapiens – innovation in Deep Brain Stimulation, acquired by Medtronic for USD200mm. Molecular Partners – a Zurich-based Biotech introducing DARPins as a new class of biologicals in ophthalmology and cancer, now on the Swiss Stock Exchange with a market cap of CHF470mm.

The Convergence in Oncology Summit
The Convergence in Oncology Summit held in Lausanne, Switzerland is an international annual assembly of industry leaders, entrepreneurs, and investors active in the field of Oncology to explore synergies that can accelerate the development of the most promising solutions to fight cancer. The annual event is attended by CEOs, entrepreneurs, investors, and thought leaders from both academia and industry to discuss and debate the key issues of global concern in Oncology.

Durham - North Carolina, USA, September 24th, 2018: SOPHiA GENETICS, leader in Data-Driven Medicine, today announced from the Personalized Medicine World Congress (PMWC) at Duke University that the company has opened operations in Boston to meet the burgeoning demand across the United States.

SOPHiA AI (SOPHiA) is the most widely used technology for genomic analysis, adopted by hundreds of university hospitals worldwide. SOPHiA has already analyzed over 250,000 genomic profiles – currently one every five minutes! Utilized in the context of hereditary disorders and cancer, SOPHiA enables clinicians to accurately detect and characterize genomic alterations. Through the company’s platform, experts can unite across borders and use their shared knowledge to efficiently deliver faster outcomes.

In the United States, SOPHiA GENETICS is already supporting more than 100 university hospitals and is rapidly expanding across the region. The company’s impact has long been recognized overseas as the global forerunner in Data-Driven Medicine. SOPHiA GENETICS is currently ranked as one of the 50 smartest companies in the world by the MIT Tech Review.

Jurgi Camblong, CEO and co-founder of SOPHiA GENETICS, commented: “We are experiencing a wide and fast adoption of our technology in North America and are very happy to open our U.S. headquarters in Boston and strengthen our team to support customers’ needs. We currently have 20 people working in the U.S. and we will be expanding to 50 within a year’s time.”

Lars Steinmetz, co-founder of SOPHiA GENETICS and professor at Stanford University added: “When we created SOPHiA GENETICS, we never expected to have such an impact worldwide. Thanks to the expertise and quality delivered by SOPHiA’s dedicated team of experts and its standardized technology SOPHiA, the company has earned the trust of the global genomics community, which is so important to truly accelerate the democratization of Data-Driven Medicine.”

São Paulo, 4^th July 2018: SOPHiA GENETICS, global leader in Data-Driven Medicine, today announced that the company has welcomed three new leading healthcare institutions, ten in total, from across the country who have adopted SOPHiA AI, the universal technology for clinical genomics analysis.

SOPHiA GENETICS is making a meaningful contribution, supporting and accelerating the adoption of clinical genomic testing in Brazil. The company’s solutions are answering healthcare institutions’ Data-Driven Medicine needs for a direct benefit to patients.

Brazilian institutions use the company’s AI technology to detect and characterize all type of disease-causing genomic alterations. This valuable information helps them better and faster diagnose their patients suffering from hereditary diseases and cancers.

As explained by Dra. Dirce Carraro, Head of the Genomics and Molecular Biology Laboratory at AC Camargo Cancer Center: “The Hereditary Cancer Solution by SOPHiA GENETICS has shown excellent reproducible results for the detection of very complex to find alterations such as SNVs, Indels and CNVs giving us the possibility to streamline the analysis quickly into our routine testing”

GeneOne is a genomics laboratory that is part of the DASA group, Latin America's largest diagnostic medicine company. Gustavo Campana, Medical Director of Clinical Analysis at DASA revealed the following:“After working with SOPHiA’s analytical technology for more than 2 years, moving towards a customized application was a natural choice for us. We truly believe SOPHiA GENETICS will become a long-lasting partner in the growth and establishment of GeneOne at the forefront of genomic testing in Brazil and Latin America”

Hospital de Amor, previously known as the Hospital de Cancer de Barretos, is a philanthropic hospital specialized in diagnosis and treatment for cancer’s patients. Their Oncogenetic unit quickly understood the power of SOPHiA AI: “Working with SOPHiA GENETICS was a logical next step for us to streamline our clinical genomic analysis processes. While our demand in Next-Generation Sequencing (NGS) both research and diagnostic continue to grow, we needed a centralized and powerful technology to analyze quickly and precisely the large amount of data. The high analytical performance, its interpretation capabilities, and the support provided has been key in our decision to adopt SOPHiA AI and join the world’s largest community in Data-Driven Medicine.” Dra. Edenir Palmero – Manager Oncogenetics Lab

In addition of SOPHiA’s rapid adoption in the Brazilian healthcare space, SOPHiA GENETICS is proud to announce that the company has recently been selected to be part of the 2018 TechEmerge Project organized by the IFC (World Bank Group) in Brazil. Participants have been given the opportunity to meet with selected healthcare providers to build innovative pilot projects in order to further accelerate the adoption of their technologies.

“Since inception, our vision has been to develop innovative technological solutions to help patients, equally wherever they live. SOPHiA acts as a real disruptor by breaking down the information silos in healthcare, meaning that the information from a patient in Paris can for instance help better diagnose and treat a patient in Rio de Janeiro.” – Dr. Jurgi Camblong, CEO and Co-Founder of SOPHiA GENETICS

Milan - Italy, June 16, 2018: SOPHiA GENETICS, global leader in Data-Driven Medicine, announced today at the European Human Genetics Conference (ESHG 2018)that it has completed the acquisition of French-based tech company Interactive Biosoftware (IBS), the creators of Alamut^® , the most used decision support software for clinical genomic data interpretation.

Alamut^® is currently deployed in over 450 hospitals and is highly complementary to SOPHiA GENETICS’ offering. This is an important milestone that will further accelerate the adoption of Data-Driven Medicine around the world.

The acquisition reinforces SOPHiA GENETICS’ commitment to continuously support hospitals and patients with powerful technologies. Interactive Biosoftware’s expertise and teams will join SOPHiA GENETICS’ workforce. A seamless onboarding will ensure Alamut^® users’ experience.  

“Interactive Biosoftware has been highly successful in providing powerful technology for experts with complex genomic interpretation needs. It is great to join SOPHiA GENETICS unique approach and position to accelerate Data-Driven Medicine’sadoption.” – André Blavier CEO & Founder at Interactive Biosoftware.

“We are very excited about the acquisition of Interactive Biosoftware. Both SOPHiA AI and Alamut^® are technologies trusted by the healthcare community and focus on patient-centric innovation. The addition of Alamut^® marks a big step in our aim to help clinicians better diagnose patients equally. With a community of now over 900 teaching hospitals using our technologies we are in a unique position to connect clinicians and enable them to share knowledge.” - Jurgi Camblong, CEO & Co-founder at SOPHiA GENETICS.

LAUSANNE, Switzerland, 26 April 2018: SOPHiA GENETICS, global leader in Data-Driven Medicine, announced today that its technology for clinical genomics, SOPHiA GENETICS artificial intelligence, has reached a key milestone in helping better diagnose 200'000 patients.

Adopted by over 430 hospitals across 60 countries, SOPHiA GENETICS AI has proven to be a robust and standardized decision support technology for clinicians. SOPHiA GENETICS is the first AI to analyze over 200,000 patients’ genomic profiles around the world. This illustrates the rapid adoption of this technology which is trusted by clinicians to support their clinical decisions.

The recent use of digital technology in healthcare is creating a new world of opportunity to help better diagnose and treat patients. The development of Next-Generation Sequencing (NGS), in particular, promises to enhance patient care for patients suffering from hereditary diseases and cancer. Six percent of the global population is affected by a hereditary disease and it is expected that one in two people will be diagnosed with cancer in the coming years. In both cases, clinical genomic analysis through NGS help to pinpoint the molecular origin driving the disease and to tackle the cause of such disease rather than act on its consequences.

Genomic data analysis and interpretation are extremely complex and presents significant challenges to be implemented in clinical practice. SOPHiA AI handles this complexity making data relevant and helping clinicians to quickly adopt clinical genomics.

The company and its technology are recognized for its innovative approach and impact on people’s lives. SOPHiA GENETICS was listed by the MIT Technology Review among the 50 Smartest Companies worldwide and more recently in Fast Company’s Top 10 Most Innovative Biotech Companies.

“When we launched SOPHiA GENETICS, we had a simple but ambitious objective, to build something that would help better diagnose and treat the maximum number of patients. We are thrilled by how rapidly SOPHiA is being adopted around the world. This illustrates the trust the healthcare industry has in our technology, and the need for a standardized approach in clinical genomics.”  

Jurgi Camblong (CEO & CO-Founder of SOPHiA GENETICS)

En créant un pôle R&D en Nouvelle-Aquitaine, la compagnie fondée par le Basque, Jurgi Camblong, mise sur la France pour renforcer son IA SOPHiA qui contribue aujourd’hui à mieux diagnostiquer 1 patient toutes les 5 minutes.

Bidart – France le 12 avril 2018, SOPHiA GENETICS, le leader mondial de la médecine basée sur les données (Data-Driven Medicine), annonce depuis le campus de l’ESTIA – Nouvelle-Aquitaine, l’ouverture d’un premier centre R&D en France. Avec l’IA SOPHiA qui a déjà aidé au diagnostic de 200’000 patients dans le monde, la tech compagnie compte sur les talents français pour muscler encore davantage sa technologie. Plus de 30 postes seront prochainement créés.

La France a pour objectif de devenir l’un des leaders mondiaux dans le domaine de l'intelligence artificielle (IA). Comme l’a proclamé le Président Emmanuel Macron il y a deux semaines lors de l’annonce d’un plan budgétaire de 1.5 milliard d’euros, afin de favoriser les échanges et collaborations entre le domaine public et le privé. L’hexagone a en effet déjà séduit plusieurs géants internationaux en les incitant à installer des centres spécialisés sur l’IA comme le sud-Coréen Samsung et les Américains Microsoft, Google et IBM.

Jurgi Camblong, CEO et co-fondateur de SOPHiA GENETICS commente : « La France est un territoire historique pour SOPHiA GENETICS dont la technologie accompagne au quotidien des cliniciens dans plus de 45 Hôpitaux Universitaires (CHU) et Centres de Lutte Contre le Cancer (CLCC). De plus, les experts français en informatique et mathématiques appliquées sont reconnus au niveau mondial. Fin 2017 déjà, nous avions investi dans une technologie développée par l’équipe du Pr. Thierry Colin à l’INRIA/INP de Bordeaux. Avec l’ouverture de ce pôle R&D dans le campus de l’ESTIA, nous allons pouvoir accélérer le développement de notre plateforme IA ».

« Le prodigieux succès que connaît SOPHiA GENETICS et sa position de leader mondial de la médecine basée sur les données font de cette arrivée en Nouvelle-Aquitaine, un véritable atout pour réaffirmer la position de la Région en tant que précurseur du développement de l’IA dans le domaine de la santé », indique Alain Rousset, Président de la Région Nouvelle-Aquitaine.

SOPHiA GENETICS qui utilise l’IA afin d’aider plus de 420 hôpitaux dans 60 pays est devenue en quelques années seulement, l’une des start-ups les plus en vue au monde. Après avoir été listée en 2017 par le MIT Tech Review parmi les 50 compagnies les plus intelligentes, c’est le magazine américain Fast Company qui cette année l’élève au rang des 10 biotech les plus innovantes.

Jurgi Camblong ajoute : « C’est incroyable de figurer dans de tels classements internationaux. Cela prouve que les entreprises européennes ont le potentiel pour devenir les leaders de demain et de définir des standards dans des domaines aussi importants que la médecine basée sur les données et l’IA ».

The Myeloid Solution by SOPHiA GENETICS is the best-in-class molecular diagnostic application which empowers clinicians to more precisely diagnose hematological disorders

Lausanne, SWITZERLAND – 06^th February 2018: SOPHiA GENETICS, global leader in Data-Driven Medicine, unveiled today the world’s first capture-based myeloid clinical solution to receive the CE-IVD mark. The standardized molecular diagnostic application represents a breakthrough in diagnostics for hematological diseases. This includes diseases such as leukemia, which account for 2.5% of all cancers worldwide, and 30% of cancers in children and young adults[1]. This test comprehensively covers genes associated with hematological disorders and provides clinicians with a complete solution which rapidly and precisely analyzes their patients’ DNA.

The CE-IVD marked Myeloid Solution by SOPHiA GENETICS guarantees unmatched performance in the analytical detection of genomic mutations responsible for myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and leukemia. It does this by providing high on-target reads percentage and coverage uniformity, even in GC-rich regions. Common technical limitations related to the analysis of key biomarkers such as CEBPA, FLT3 and CALR are now overcome with this standardized solution.

The newly approved CE-IVD Myeloid Solution by SOPHiA GENETICS represents a major advancement in the personalization of cancer care. It will facilitate access for patients around the world to a comprehensive diagnostic solution that will identify approved treatment options based on the molecular footprint of each individual’s cancer. This will aid the pharmaceutical industry to optimize biomarker-driven drug development and drug access to the right patients.

Though death rates associated with hematological disorders have decreased significantly in recent years, the number of new cases is steadily increasing. SOPHiA GENETICS’ CE-IVD certified Myeloid Solution alleviates the time and complexity burden of traditional diagnostic technologies with a standardized and easy to adopt solution which empowers clinicians to more precisely diagnose patients with hematological disorders.

---

[1]http://www.euro.who.int/__data/assets/pdf_file/0005/97016/4.1.-Incidence-of-childhood-leukaemia-EDITED_layouted.pdf